Company highlighted recent pipeline advances in a variety of neuroscience indications during its third-quarter earnings report.
The last full week of October was action-packed for Biogen Inc., with updated Phase II data for the Alzheimer's drug BAN2401 and progress for a number of other neuroscience assets in the pipeline, but also two mid-stage failures – vixotrigine in sciatica and dapirolizumab pegol in lupus.
The pipeline update comes at a time of concern about coming competition for the company's rare disease drug Spinraza and...
Optimizing Drug Pipelines With Biophysical Methods”, your view into how using biophysical techniques can enhance and streamline processes throughout the drug discovery and validation cycle.
CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.
A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand
GSK will assume full control of mRNA shots in infectious disease, allowing CureVac to cut costs and pivot its research to oncology.
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
